TY - JOUR
T1 - Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer
T2 - Combined analysis of two cohorts
AU - Sharma, Priyanka
AU - López-Tarruella, Sara
AU - García-Saenz, Jose Angel
AU - Ward, Claire
AU - Connor, Carol S.
AU - Gómez, Henry L.
AU - Prat, Aleix
AU - Moreno, Fernando
AU - Jerez-Gilarranz, Yolanda
AU - Barnadas, Augusti
AU - Picornell, Antoni C.
AU - Del Monte-Millán, Maria
AU - Gonzalez-Rivera, Milagros
AU - Massarrah, Tatiana
AU - Pelaez-Lorenzo, Beatriz
AU - Palomero, María Isabel
AU - González Del Val, Ricardo
AU - Cortes, Javier
AU - Rivera, Hugo Fuentes
AU - Morales, Denisse Bretel
AU - Márquez-Rodas, Iván
AU - Perou, Charles M.
AU - Wagner, Jamie L.
AU - Mammen, Joshua M.V.
AU - McGinness, Marilee K.
AU - Klemp, Jennifer R.
AU - Amin, Amanda L.
AU - Fabian, Carol J.
AU - Heldstab, Jaimie
AU - Godwin, Andrew K.
AU - Jensen, Roy A.
AU - Kimler, Bruce F.
AU - Khan, Qamar J.
AU - Martin, Miguel
N1 - Publisher Copyright:
©2016 AACR.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. Experimental Design: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of carboplatin (AUC 6) + docetaxel (75 mg/m2) given every 21 days x 6 cycles. pCR (no evidence of invasive tumor in the breast and axilla) and residual cancer burden (RCB) were evaluated. Results: Among 190 patients, median tumor size was 35 mm, 52% were lymph node positive, and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0 + 1 rates were 55% and 68%, respectively. pCRs in patients with BRCA-associated and wild-type TNBC were 59% and 56%, respectively (P = 0.83). On multivariable analysis, stage III disease was the only factor associated with a lower likelihood of achieving a pCR. Twenty-one percent and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event. Conclusions: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC. These results are comparable with pCR achieved with the addition of carboplatin to anthracycline-taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies.
AB - Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. Experimental Design: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of carboplatin (AUC 6) + docetaxel (75 mg/m2) given every 21 days x 6 cycles. pCR (no evidence of invasive tumor in the breast and axilla) and residual cancer burden (RCB) were evaluated. Results: Among 190 patients, median tumor size was 35 mm, 52% were lymph node positive, and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0 + 1 rates were 55% and 68%, respectively. pCRs in patients with BRCA-associated and wild-type TNBC were 59% and 56%, respectively (P = 0.83). On multivariable analysis, stage III disease was the only factor associated with a lower likelihood of achieving a pCR. Twenty-one percent and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event. Conclusions: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC. These results are comparable with pCR achieved with the addition of carboplatin to anthracycline-taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies.
UR - http://www.scopus.com/inward/record.url?scp=85012248487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012248487&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-0162
DO - 10.1158/1078-0432.CCR-16-0162
M3 - Article
C2 - 27301700
AN - SCOPUS:85012248487
SN - 1078-0432
VL - 23
SP - 649
EP - 657
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -